



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/589,095	10/01/2008	Yuelian Xu	NEU0027US2	5478
23413	7590	08/18/2009	EXAMINER	
CANTOR COLBURN, LLP			JAISLE, CECILIA M	
20 Church Street			ART UNIT	PAPER NUMBER
22nd Floor			1624	
Hartford, CT 06103				
NOTIFICATION DATE	DELIVERY MODE			
08/18/2009	ELECTRONIC			

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

usptopatentmail@cantorcolburn.com

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/589,095	XU ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Cecilia M. Jaisle	1624	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 09 August 2006.  
 2a) This action is **FINAL**.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-30,39 and 41 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) \_\_\_\_\_ is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) 1-30,39 and 41 are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO/SB/08)  
 Paper No(s)/Mail Date \_\_\_\_\_.  
 4) Interview Summary (PTO-413)  
 Paper No(s)/Mail Date \_\_\_\_\_.  
 5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_.

**DETAILED OFFICE ACTION*****Lack of Unity***

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions that are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- I. Claims 1-10, 11, 12, 16-20, 25-30, 39 and 41, drawn to substituted imidazo[1,2-b]pyridazine compounds of Formula I (Ex. 1), classified in class 544, subclass 236; pharmaceutical compositions, in class 514, subclass 248.
- II. Claims 1-10, 13, 14, 16-18, 21, 22, 25-30, 39 and 41, drawn to Formula I substituted imidazo[1,5-b]pyridazine compounds (Ex. 2), classified in class 544, subclass 238; pharmaceutical compositions, in class 514, subclass 248.
- III. Claims 1-10, 15-18, 23-30, 39 and 41, drawn to substituted [1,2,4]triazolo[4,3-b]pyridazine compounds of Formula I (Ex. 3), classified in class 544, subclass 236; and pharmaceutical compositions, classified in class 514, subclass 248.
- IV. Claims 1-10, 17, 18, 25-30, 39 and 41, drawn to all other compounds of Formula I, not provided for above, variously classified in classes 544 and 546, their pharmaceutical compositions, variously classified in class 514.

Each group set forth above lacks unity with each other group, i.e., there is no single general inventive concept. The unique special technical features in

each group are the identities in Formula I of the bicyclic nitrogen-containing ring.

The technical relationship among the inventions does not involve at least one common or corresponding special technical feature. The expression "special technical feature" is defined as meaning those technical features that define the contribution which each claimed invention, considered as a whole, makes over the prior art. In this case, a reference that could be used to reject Formula I compounds, where the bicyclic ring is imidazo[1,2-b] pyridazine of Group I could not be used to reject compounds of Formula I, of any other of Groups II-IV.

Group I invention has special technical features not common to Groups II-IV and would be expected to be useful, e.g., as intermediates to substituted imidazo[1,2-b] pyridazines (US 2009 0176788, Falcó). Group II invention has special technical features not common to Groups I, III and IV and would be expected to be useful, e.g., as intermediates to P13 kinase inhibitors (US 2009 0163489, Booket, et al.). Group III invention has special technical features not common to Groups I, II and IV and would be expected to be useful, e.g., as intermediates to antivirals (US 2009 0170856, Billedeau, et al.).

To preserve a right to petition, the reply to this Office Action must distinctly and specifically point out supposed errors in the restriction requirement or the election will be treated as without traverse. If applicant traverses on the basis that the inventions are not patentably distinct, applicant should submit evidence, or identify evidence now of record, showing the inventions to be obvious variants or clearly admit this on the record. In either case, if the examiner finds one

invention unpatentable over the prior art, the evidence or admission may be used to reject the other invention under 35 USC 103(a).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cecilia M. Jaisle whose telephone number is 571-272-9931. The examiner can normally be reached on Monday through Friday; 8:30 am through 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Cecilia M. Jaisle/  
Patent Examiner, AU 1624

**/James O. Wilson/  
Supervisory Patent Examiner, AU 1624**